Denosumab for the treatment of therapy-induced bone loss in non-metastatic breast cancer
Status Discontinued
Decision Selected
Process STA pre-2018
Referral date 01 April 2009
Topic area
  • Cancer
  • Musculoskeletal

Cancer reform strategy Batch 6

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Laura Gibson
Executive Lead: Gillian Leng
Project manager: Jeremy Powell
Technical Lead: Scott Goulden


Key events during the development of the guidance:

Date Update
4 January 2010 The manufacturer of denosumab has indicated that they will not make a submission for this appraisal. We have therefore suspended the appraisal.
2 August 2010 Denosumab has not received a separate marketing authorisation for this indication. The Department of Health have therefore removed this appraisal from NICE’s work programme.

For further information on our processes and methods, please see our CHTE processes and methods manual